search
Back to results

China Stroke Secondary Prevention Trial (CSSPT)

Primary Purpose

Stroke, Transient Ischemic Attack

Status
Withdrawn
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Folic Acid
Vitamin B6
Vitamin B12
placebo
placebo
placebo
Sponsored by
Xijing Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Stroke focused on measuring folic acid, B vitamins, secondary prevention, stroke, randomized controlled trial, homocysteine

Eligibility Criteria

35 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients presenting within one months of ischemic stroke (ischemic or hemorrhagic) or TIA
  • Homocysteine level ≥ 15μmol/L
  • Agree to take study medication;Be geographically accessible for follow-up
  • Provide written informed consent

Exclusion Criteria:

  • Other cause of ischemic stroke (cardioembolism; stroke of other determined etiology, and stroke of undetermined etiology according to TOAST subtypes) or hemorrhagic stroke (intracranial vascular malformations; cerebral amyloid angiopathy; trauma and bleeding disorders etc)
  • Use of vitamin supplements containing folate, B6 or B12
  • Pregnancy or women of child-bearing potential who are at risk of pregnancy
  • Limited life expectancy

Sites / Locations

  • Xijing Hosptial

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

vitamin supplements

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Recurrent stroke
Myocardial infarction
Death due to other vascular causes

Secondary Outcome Measures

TIA
Revascularization procedures
Dementia
Depression

Full Information

First Posted
March 15, 2011
Last Updated
August 18, 2014
Sponsor
Xijing Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01317849
Brief Title
China Stroke Secondary Prevention Trial
Acronym
CSSPT
Official Title
Folic Acid and B Vitamins for Secondary Prevention of Stroke : A Double-blinded Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2014
Overall Recruitment Status
Withdrawn
Why Stopped
financial assistance financial assistance financial assistance financial assistance financial assistance without financial assistance
Study Start Date
July 2011 (undefined)
Primary Completion Date
June 2016 (Anticipated)
Study Completion Date
June 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Xijing Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death.
Detailed Description
The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death in patients with recent stroke or transient ischemic attack (TIA). All patients presenting to one of the participating neurologists or general physicians within one months of stroke (ischemic or hemorrhagic) or TIA (eye or brain) are eligible for this trial. Eligible patients will be randomized in a double-blinded fashion to receive multi-vitamins or placebo. The primary outcome event is the composite event "stroke, myocardial infarction, or death from any vascular cause", whichever occurs first. Our target is to recruit a total of 8,000 patients over the two years with a median follow-up of 3 years. Recruitment to the trial began in July 2011 and is planned to continue until December 2013. The investigators aim to complete final follow-up by the end of 2016.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Transient Ischemic Attack
Keywords
folic acid, B vitamins, secondary prevention, stroke, randomized controlled trial, homocysteine

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
vitamin supplements
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Folic Acid
Other Intervention Name(s)
folate
Intervention Description
0.8mg
Intervention Type
Drug
Intervention Name(s)
Vitamin B6
Other Intervention Name(s)
Pyridoxine
Intervention Description
10mg
Intervention Type
Drug
Intervention Name(s)
Vitamin B12
Other Intervention Name(s)
Cyanocobalamin
Intervention Description
500ug
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
0.8 mg
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
10mg
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
500ug
Primary Outcome Measure Information:
Title
Recurrent stroke
Time Frame
3 years
Title
Myocardial infarction
Time Frame
3 years
Title
Death due to other vascular causes
Time Frame
3 years
Secondary Outcome Measure Information:
Title
TIA
Time Frame
3 years
Title
Revascularization procedures
Time Frame
3 years
Title
Dementia
Time Frame
3 years
Title
Depression
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients presenting within one months of ischemic stroke (ischemic or hemorrhagic) or TIA Homocysteine level ≥ 15μmol/L Agree to take study medication;Be geographically accessible for follow-up Provide written informed consent Exclusion Criteria: Other cause of ischemic stroke (cardioembolism; stroke of other determined etiology, and stroke of undetermined etiology according to TOAST subtypes) or hemorrhagic stroke (intracranial vascular malformations; cerebral amyloid angiopathy; trauma and bleeding disorders etc) Use of vitamin supplements containing folate, B6 or B12 Pregnancy or women of child-bearing potential who are at risk of pregnancy Limited life expectancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gang Zhao, MD
Organizational Affiliation
the Department of Neurology , Xijing Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Xijing Hosptial
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710032
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
23490255
Citation
Liu X, Shi M, Xia F, Han J, Liu Z, Wang B, Yang F, Li L, Wu S, Wang L, Liu N, Lv Y, Zhao G. The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double-blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke. Int J Stroke. 2015 Feb;10(2):264-8. doi: 10.1111/ijs.12017. Epub 2013 Mar 12.
Results Reference
background

Learn more about this trial

China Stroke Secondary Prevention Trial

We'll reach out to this number within 24 hrs